Speciality: Orthopedics
Description:
A warm welcome to all the medical professionals in this interesting session on use of JAK inhibitor and TNF inhibitor drugs in spondyloarthritis. We have Dr. Jyotsna Oak, Dr. Shashank Akerkar and Dr. Sourabh Malviya to lead the session.
Spondyloarthritis is a type of arthritis where the spine is affected and, in some cases, the joints of the arms and legs are also affected. It can also involve the skin, intestines and eyes. The primary symptom observed in most patients is low back pain, mostly axial spondyloarthritis.
It is thought that spondyloarthritis develops through the interaction of genetic and environmental factors. Further, spondyloarthropathies (SpA) is recognised as autoimmune disease as it is strongly associated with HLA-B27, a gene variant that controls immune responses.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Adult overdose deaths on the rise
2.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
3.
To automate the biopharmaceutical facilities of Reliance Life Sciences, ABB India has won the contract.
4.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
5.
New study links air pollution with higher rates of head and neck cancer
1.
Liquid Biopsy in Oncology: Innovations in Cancer Detection, Monitoring, and Clinical Use
2.
Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring
3.
The Importance of Maintaining Normal Calcium Levels in Your Body
4.
The Truth About Marijuana and Its Effect on Mental Health
5.
Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
5.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation